Evidence map›Paper›PMID 27199125›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2016

Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow.

Sanjeev A Datar, Wenhui Gong, Youping He, Michael Johengen, Rebecca J Kameny, Gary W Raff, Emin Maltepe, Peter E Oishi, Jeffrey R Fineman

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Lymphatic dysfunction in critical illness.Current opinion in pediatrics · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sanjeev A DatarDepartment of Pediatrics, University of California, San Francisco, San Francisco, California; sanjeev.datar@ucsf.edu.
Wenhui GongDepartment of Pediatrics, University of California, San Francisco, San Francisco, California;
Youping HeDepartment of Pediatrics, University of California, San Francisco, San Francisco, California;
Michael JohengenDepartment of Pediatrics, University of California, San Francisco, San Francisco, California;
Rebecca J KamenyDepartment of Pediatrics, University of California, San Francisco, San Francisco, California;
Gary W RaffDepartment of Surgery, University of California, Davis, Davis, California.
Emin MaltepeDepartment of Pediatrics, University of California, San Francisco, San Francisco, California;
Peter E OishiDepartment of Pediatrics, University of California, San Francisco, San Francisco, California; Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California; and.
Jeffrey R FinemanDepartment of Pediatrics, University of California, San Francisco, San Francisco, California; Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California; and.
University of California, San Francisco · USUniversity of California, Davis · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
PERINATAL PULMONARY HYPERTENSION: DEVELOPMENT MEDIATORSR01HL061284 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FINEMAN, JEFFREY R · 1999 to 2016
$8.3M
Research Training in Pediatric Critical Care MedicineT32HD049303 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFREY R FINEMAN · 2006 to 2026
$3.1M
Altered Lymphatics in an Ovine Cardiac Model of Increased Pulmonary Blood FlowK08HL116763 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DATAR, SANJEEV A. · 2013 to 2016
$580k
NHLBI NIH HHS K08 HL116763NHLBI NIH HHS R01 HL061284NICHD NIH HHS T32 HD049303NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

Associated abnormalities of the lymphatic circulation are well described in congenital heart disease. However, their mechanisms remain poorly elucidated. Using a clinically relevant ovine model of a congenital cardiac defect with chronically increased pulmonary blood flow (shunt), we previously demonstrated that exposure to chronically elevated pulmonary lymph flow is associated with: 1) decreased bioavailable nitric oxide (NO) in pulmonary lymph; and 2) attenuated endothelium-dependent relaxation of thoracic duct rings, suggesting disrupted lymphatic endothelial NO signaling in shunt lambs. To further elucidate the mechanisms responsible for this altered NO signaling, primary lymphatic endothelial cells (LECs) were isolated from the efferent lymphatic of the caudal mediastinal node in 4-wk-old control and shunt lambs. We found that shunt LECs (n = 3) had decreased bioavailable NO and decreased endothelial nitric oxide synthase (eNOS) mRNA and protein expression compared with control LECs (n = 3). eNOS activity was also low in shunt LECs, but, interestingly, inducible nitric oxide synthase (iNOS) expression and activity were increased in shunt LECs, as were total cellular nitration, including eNOS-specific nitration, and accumulation of reactive oxygen species (ROS). Pharmacological inhibition of iNOS reduced ROS in shunt LECs to levels measured in control LECs. These data support the conclusion that NOS signaling is disrupted in the lymphatic endothelium of lambs exposed to chronically increased pulmonary blood and lymph flow and may contribute to decreased pulmonary lymphatic bioavailable NO.

Indexed as

AnimalsAnimals, NewbornCells, CulturedDisease Models, AnimalDown-RegulationEndothelial CellsEnzyme InhibitorsHeart Defects, CongenitalLymphLymphatic DiseasesLymphatic VesselsNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIPulmonary CirculationReactive Oxygen SpeciesEnzyme InhibitorsNitric OxideNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIReactive Oxygen Speciesnitric oxide signalingnitric oxide synthase

Identifiers

PMID27199125
PMCPMC4967199
OpenAlexW2370071140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.